close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Viagra-for Heart Disease?

November 1, 2005

Viagra may offer more than just a relatively quick-fix for men's sex lives. A new study suggests that Viagra (sildenafil) may also slow the progress of some types of heart disease.

Researchers at Johns Hopkins claim to have found evidence that Viagra effects the human heart, according to a study published in the 25 October 2005 issue of journal Circulation and reported by MedPage Today on 25 October.

"The main thing we've found is that sildenafil essentially blunts the cardiac-stimulating effects of a synthetic catecholamine, dobutamine," said David Kass, MD, according to MedPage Today.

Dr. Kass and colleagues have previously shown that sildenafil can reverse or prevent cardiac hypertrophy in mice. (See previous report in MedPage Today.) The more recent study published in Circulation suggests that sildenafil has a similar effect on humans, although more clinical studies are needed to prove it, according to Dr. Kass.

The findings may also explain why the "heart-pounding excitement of Viagra-enhanced sex" seems to be relatively safe for men who have heart disease, according to MedPage Today.

Dr. Kass said that the results "would suggest that all along there has been some sort of blunting effect, so that heart is not racing as much as would have been. In retrospect, it may explain why the drug has been so well-tolerated even in patients with coronary disease." He believes that the study results should prompt further clinical research into potential additional therapeutic uses of Viagra and similar drug-compounds.

Recent Study

The Circulation study included 35 healthy volunteers in a randomized, controlled, double-blind placebo format. Researchers tested heart function four times: at baseline, after a dobutamine challenge, at a second baseline, and after dobutamine challenge combined with either Viagra (sildenafil) (100 mg) or placebo.

Results showed that dobutamine's effects on patients taking Viagra at the second challenge were significantly less pronounced than in the initial response. In contrast, volunteers receiving placebo group showed similar reactions to those seen in the initial response:

  • In volunteers not taking Viagra, the peak power index rose 254 mmHg per second from the baseline of about 300; in volunteers taking Viagra, it rose only 164 mmHg.
  • In volunteers not taking Viagra, the ejection fraction rose by 15%; in patients taking Viagra, it rose only 4%.
  • Ventricular end-systolic elastance in volunteers not taking Viagra rose 2.52 mmHg/mL; in volunteers in whom Viagra was co-administered, the measurement was only 0.84.

All of these differences had high statistical significance.

Viagra works by inhibiting the enzyme phosphodiesterase 5 (PDE5), which breaks down cyclic GMP (cGMP). This inhibition leads to increased levels of cGMP, which in turn causes the vasodilation that accounts for Viagra's positive effect on erectile function.

However, although cGMP also regulates cardiac function and counters beta-adrenergic stimulation, scientists until now believed that not enough PDE5 was present in the heart-muscle significantly to affect its metabolism.

These study results overturn that view, according to Dr. Kass, who reportedly said, "The enzyme really is in there and sildenafil really does have an effect on the human heart."

Sources:
Little Blue Pill May Put Brakes on Some Heart Disease, MedPage Today, 25 October 2005.
Sildenafil Inhibits Beta-Adrenergic-Stimulated Cardiac Contractility in Humans. Borlaug BA et al., Circulation, volume 112, pages 112:2642-2649, 2005.
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Takimoto E et al., Nature Medicine, volume 11(2), pages 214-222, February 2005.

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...